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The puri®cation and crystallization of two different crystal forms of
the two-domain protein bovine cyclophilin 40 is reported. Tetragonal
crystals grown in methyl pentanediol belong to space group P4222
with unit-cell parameters a = 94.5, c = 118.3 AÊ . Long thin needles
grown from PEG belong to space group C2 with unit-cell parameters
a = 125.71, b = 47.3, c = 74.6 AÊ ,  = 93.90. The N-terminal 170 amino
acids have signi®cant homology with the well characterized human
cyclophilin A. The C-terminal domain is largely made up of three
copies of the tetratricopeptide repeat motif thought to be involved in
mediating protein±protein interactions. Cyclophilins are frequently
found as domains in larger multidomain proteins. To date, only X-ray
structures of single-domain cyclophilins have been reported, and this
work provides the ®rst example of the puri®cation and crystallization
of a larger protein containing a cyclophilin domain.
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1. Introduction
Cyclophilins are phylogenetically highly
conserved proteins which act as peptidyl±
prolyl cis±trans isomerases (PPIases) and are
involved in protein folding/refolding as well as
protein±protein interactions (Galat &
Metcalfe, 1995). The ®rst member of this
expanding family to be discovered was the
18 kDa human cyclophilin A (hCyP18) which
was identi®ed by its binding to the fungal
peptide immunosuppressant cyclosporin A
(CsA) (Handschumacher et al., 1984). The
X-ray structures of cyclophilin A and of its
complex with CsA have been determined
(Kallen et al., 1991; P¯ugl et al., 1993) and show
the eight-stranded barrel structure conserved
in all cyclophilin domains.
Larger multidomain proteins such as
CyP150 from natural killer cells (Anderson et
al., 1993) and RanBP2 (Yokoyama et al., 1995)
also contain single cyclophilin domains. The
two-domain cyclophilin 40 (CyP40) protein
family has been found in mammals (Kieffer et
al., 1992 1993; Ratajczak et al., 1993) and yeast
(Weisman et al., 1996; Duina et al., 1996), and
was originally isolated and characterized in
association with the unactivated non-DNA
binding form of the oestrogen receptor
(Ratajczak et al., 1993). CyP40 is also present
as one of several components of mature
unactivated complexes of the glucocorticoid
and progesterone receptors (reviewed in Pratt
& Toft, 1997). The major chaperones, hsp90
and hsp70, are included as non-hormone-
binding components within these steroid-
receptor complexes, together with p23 and the
immunophilins FKBP51 and FKBP52 (Pratt &
Toft, 1997), which are cellular targets of the
immunosuppressant FK506 (Galat & Metcalfe,
1995). CyP40, FKBP51 and FKBP52 belong to
a distinct class of proteins which display an
N-terminal immunophilin-like domain with
overlapping regions for immunosuppressant
drug interaction and isomerase activity, toge-
ther with a conserved C-terminal tetra-
tricopeptide repeat (TPR) domain proposed to
mediate protein±protein interaction
(Ratajczak et al., 1993; Nair et al., 1997).
Through this conserved C-terminal region,
these immunophilins target a common inter-
action site in hsp90, resulting in the formation
of separate immunophilin±hsp90±steroid-
receptor complexes (Nair et al., 1997; Radanyi
et al., 1994; Hoffmann & Handschumacher,
1995; Ratajczak & Carrello, 1996; Young et al.,
1998; Carrello et al., 1999). CyP40 and its
partner immunophilins appear to have a
coordinate role with hsp90 in the functional
control of receptor activity (Pratt & Toft,
1997).
In vitro folding assays have shown that
Cyp40 and FKBP52 can function as molecular
chaperones, similar to hsp90 and hsp70, by
holding substrate proteins in a partially folded
conformation (Freeman et al., 1996; Bose et al.,
1996). The expression of these immunophilins
is ubiquitous (Ratajczak et al., 1993; Kieffer et
al., 1993; Nair et al., 1997) and there is evidence
for their association with hsp90 independently
of steroid receptors (Pratt & Toft, 1997). Cpr6
and Cpr7 are the only Saccharomyces cerevi-
siae homologues of Cyp40, and both associate
with hsp90 (Duina et al., 1996). Mutations
which decrease the level of hsp90 expression,
coupled with a deletion of Cpr7, cause a
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signi®cant reduction in the rate of cell
growth (Duina et al., 1996). The involvement
of wis2, the corresponding CyP40 homolog
in Schizosaccharomyces pombe, in regu-
lating the G2-mitosis transition (Weisman et
al., 1996) is consistent with this observation.
Hsp90 in association with Cpr7 has also been
shown to participate in the negative regula-
tion of the heat-shock response in S. cere-
visiae (Duina et al., 1998). Taken together,
these results suggest that Cyp40 plays a
major role in hsp90-mediated signal-trans-
duction pathways.
2. Materials and methods
2.1. Expression, puri®cation and
characterization
Expression plasmids for untagged wild-
type bovine CyP40 (bCyP40) and the
cyclophilin fused to glutathione S-trans-
ferase (GST) have been described
(Ratajczak & Carrello, 1996; Carrello et al.,
1999).
GST-fused recombinant cyclophilin 40
(GST-bCyP40 WT; Ratajczak & Carrello,
1996) was expressed following a 4 h induc-
tion with 0.4 mM IPTG (ICN/FLOW). Cell
pellets were frozen at 253 K, thawed slowly
on ice and solubilized in lysis buffer [20 mM
Tris buffer pH 7.8 containing 150 mM NaCl,
2 mM EDTA, 5 mM DTT, 1%(v/v) Triton
X-100 and 5 mM benzamidine]. Lysozyme
(ICN/FLOW) was added to 0.1%(w/v) and
the cell suspension incubated on ice for 1 h.
An equal volume of distilled water at 277 K
was added and the cell suspension was
mixed and centrifuged at 48400g for 60 min.
The resulting supernatant was frozen at
253 K, thawed on ice and ®ltered (0.45 mm)
prior to puri®cation. The protein extract was
puri®ed to near homogeneity using four
puri®cation steps. (i) Glutathione Sepharose
(Pharmacia) af®nity chromatography:
protein was applied in buffer A (50 mM
Tris±HCl pH 7.5 buffer) and GST-tagged
protein was eluted with buffer A containing
reduced 25 mM glutathione (Sigma). (ii)
Anion-exchange chromatography: protein
from the glutathione Sepharose chromato-
graphy was applied to Resource-Q resin
(Pharmacia) in buffer A. Elution with a
linear gradient from buffer A to buffer A
plus 1 M NaCl gave peak fractions which
were pooled, concentrated, quantitated for
protein concentration by the Bradford
method and dialysed overnight against
buffer A. (iii) Thrombin cleavage: GST
fusion protein was cleaved with puri®ed
thrombin at a ratio of 1:100 for 90 min at
room temperature. (iv) Cleaved protein was
subjected to a second round of chromato-
graphy on Resource-Q resin as already
described, followed by a ®nal af®nity chro-
matography step on glutathione Sepharose.
Induction and harvesting of the non-
fusion version of the protein was essentially
as described above for the GST-bCyp40 WT
protein. Puri®cation to near homogeneity
was achieved in two ion-exchange steps. The
cell extract was applied to Q Sepharose
(Amersham Pharmacia Biotech) in buffer A,
the column was washed to baseline and then
developed with a gradient of buffer A plus
1 M NaCl. Protein was eluted with 150 mM
NaCl and fractions were analysed on 12%
SDS±PAGE gels followed by staining with
Coomassie Blue. Fractions containing
bCyP40 were pooled and dialysed overnight
at 277 K against 20 mM Tris pH 8.0 buffer
(buffer B). The protein sample was applied
to Mono-Q resin (PAB) in buffer B, and
retained protein was eluted with a gradient
of buffer B plus 0.5 M NaCl. Positive frac-
tions were pooled and concentrated.
Dynamic light-scattering analysis of the
puri®ed protein (DynaPro-801 with Micro-
sampler attatchment, Protein Solutions,
Inc.) showed it to be essentially mono-
disperse and stable, with an estimated
molecular weight of 43 kDa.
The protein was further characterized by
electrospray ionization mass spectrometry
on a Micromass Platform II spectrometer.
The sample was introduced into the instru-
ment stream via an infusion pump and the
M/Z spectrum was deconvoluted using the
MaxEnt algorithm.
2.2. Crystallization
The hanging-drop vapour-diffusion
method was used to grow crystals in 24-well
Linbro plates. In all trials, crystals could only
be obtained at 277 K.
Tetragonal crystals were grown by equili-
brating a 4 ml drop of protein solution
against 1 ml of well solution. The well solu-
tion consisted of 470±490 ml MPD, 100 ml
1 M imidazole pH 6.5, 200±360 ml 50%(v/v)
glycerol solution and 50±230 ml water. The
drop consisted of 2 ml protein solution and
2 ml well solution. The protein solution
consisted of protein at between 10 and
80 mg mlÿ1 in 20 mM Tris buffer pH 8
containing 100 mM NaCl.
The morphology of the crystals in most
drops was poorly de®ned and teardrop-
shaped crystals grew with dimensions of
0.05 mm. Addition of 1% glycerol and 5±
10 mM DTT were found to improve crystal
size and morphology (Fig. 1a), with crystals
growing to 0.2  0.15  0.15 mm. The unit-
cell dimensions are a = 94.5, c = 118.3 AÊ . A
complete data set to a resolution of 2.6 AÊ
has been collected on an Enraf±Nonius
rotating-anode X-ray generator with a MAR
Research 300 image plate.
Monoclinic needles were obtained using
12%(v/v) PEG as precipitant. The 1 ml well
solution was composed of 240 ml of a 50%
solution of PEG 2000, 100 ml 1 M cacody-
late, 50 ml 1 M HCl, 200 ml 50% glycerol
solution and 410 ml water. The 4 ml hanging
drop consisted of 2 ml well solution plus 2 ml
protein at 10±80 mg mlÿ1 in 20 mM Tris pH
8 buffer containing 100 mM NaCl. Very long
thin plate-like needles grew within hours
with typical dimensions 2  0.01 
0.005 mm. These crystals are monoclinic
with space group C2. Unit-cell parameters
are a = 125.71, b = 47.3, c = 74.6 AÊ , = 93.90.
These thin needle crystals typically diffract
to a resolution of 3.6 AÊ on a rotating-anode
X-ray source, and a complete data set has
been collected.
Figure 1
Pictures of the monoclinic and tetragonal crystal
forms of Cyp40.
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3. Discussion
The amino-acid sequence for bCyP40 is
shown in Fig. 2(a) and shares 94% identity
with the human homologue. Mass spectro-
metry gives a molecular mass of 40500 Da.
The calculated molecular mass of the
sequence shown in Fig. 2 is 40620 Da, which
suggests that the N-terminal methionine
residue is removed post-translationally. The
calculated molecular mass of the sequence
omitting the N-terminal methionine is
40489 Da.
The cyclophilin domain, consisting of the
N-terminal 187 residues, is very well
conserved between the bovine and human
proteins, with differences in only ®ve resi-
dues. The N-terminal domain is 61% iden-
tical to hCyP18 and shows an even better
homology (64%) with the so-called diver-
gent class of cyclophilins (Taylor et al., 1998),
which have an additional seven amino-acid
loop inserted at positions 60±67 (Fig. 2a).
Another feature of this divergent class of
cyclophilins is that the active-site trypto-
phan, shown to be important in binding CsA
in hCyP18 (P¯ugl et al., 1994), is replaced by
a histidine. This change may explain the
reduction of the IC50 values for CsA from
20 nM for hCyP18 to 300 nM for hCyP40
(Kieffer et al., 1992). The CyP40/CsA/calci-
neurin Ki was 320 nM, compared with the
CyP18/CsA/calcineurin Ki of 195 nM, and
CyP40 was found to compete with CyP18 for
binding to calcineurin in the presence of
CsA (Kieffer et al., 1993).
The C-terminal 150 amino acids (residues
188±359) of hCyP40, comprising the TPR
and putative calmodulin-binding domains, is
31% homologous with the corresponding
region of FKBP59. An X-ray structure is
available for the TPR domain of the human
protein PP5 (Das et al., 1998) which shows
that each TPR motif consists of two helices
of about 14 amino acids which are linked by
a tight turn. The predicted secondary struc-
ture of the C-terminal CyP40 domain is
shown in Fig. 2(b), along with a sequence
alignment between human phosphatase and
bCyP40. Helical regions of the predicted
TPR motifs are also shown.
The PP5 crystal structure (Das et al., 1998)
shows that the putative calmodulin-binding
domain of CyP40 consists of an -helix
approximately 30 amino acids in length. The
secondary-structure prediction (Rost et al.,
1994) of the CyP40 sequence gives a strongly
predicted C-terminal helix of 28 amino acids
in length. This corresponds to a length of
42 AÊ and is close to the conserved b cell
dimension of the monoclinic needle form of
CyP40. The b axis also corresponds to the
Figure 2
(a) Sequence alignment of human cyclophilin A (CYPH_HUMAN), nematode cyclophilin 3 (CYP3_CAEEL),
human and bovine cyclophilin 40 (CYP4_HUMAN, CYP4_BOVIN) and human protein phosphatase 5
(PPP5_HUMAN). Sequences from the Swiss±Prot database were aligned using the program MultAlign and
represent the entire sequence of the cyclophilins aligned against the N-terminal 150 amino acids from PP5. The
TPRs of PP5 are shown in bold. Numbering applies to the amino-acid sequence of bovine CyP40. (b) Alignment
of the three TPR motifs of bCyP40 against the N-terminal 150 TPR domain of PP5. The six helices associated
with the three TPR motifs determined in the the X-ray structure of PP5 (Das et al., 1998) are underlined. The C-
terminal extension of 28 amino acids is the predicted helical calmodulin-binding site. The program MultAlign
(Corpet, 1988) was used for amino-acid alignment.
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long and fast-growing needle axis, and it is
reasonable to suggest that it is this calmo-
dulin-binding helix which determines the
length of the b axis and also the kinetics and
morphology of the monoclinic needle crys-
tals.
We thank Violet R. Anderson for the
mass spectrometry.
References
Anderson, S. K., Gallinger, S., Roder, J., Frey, J.,
Young, H. A. & Ortaldo, J. R. (1993). Proc. Natl
Acad. Sci. USA, 90, 542±546.
Bose, S., Weikl, T., Bugl, H. & Buchner, J. (1996).
Science, 274, 1715±1717.
Carrello, A., Ingley, E., Minchin, R. F., Tsai, S. &
Ratajczak, T. (1999). J. Biol. Chem. 274, 2682±
2689.
Corpet, F. (1988). Nucleic Acids Res. 16, 10881±
10890.
Das, A. K., Cohen, P. T. W. & Barford, D. (1998).
EMBO J. 17, 1192±1199.
Duina, A. A., Kalton, H. M. & Gaber, R. F. (1998).
J. Biol. Chem. 273, 18974±18978.
Duina, A. A., Marsh, J. A. & Gaber, R. F. (1996).
Yeast, 12, 943±952.
Freeman, B. C., Toft, D. O. & Morimoto, R. I.
(1996). Science, 274, 1718±1720.
Galat, A. & Metcalfe, S. M. (1995). Prog. Biophys.
Mol. Biol. (1995). 63, 67±118.
Handschumacher, R. E., Harding, M. W., Rice, J.
& Drugge, R. J. (1984). Science, 226, 544±547.
Hoffmann, K. & Handschumacher, R. E. (1995).
Biochem. J. 307, 5±8.
Kallen, J., Spitzfalden, C., Zurini, M. G. M., Wider,
G., Widmer, H., Wuthrich, K. & Walkinshaw,
M. D. (1991). Nature (London), 353, 276±279.
Kieffer, L. J., Seng, T. W., Li, W., Osterman, D. G.,
Handschumacher, R. E. & Bayney, R. M.
(1993). J. Biol. Chem. 268, 12303±12310.
Kieffer, L. J., Thalhammer, T. & Handschumacher,
R. E. (1992). J. Biol. Chem. 267, 5503±5507.
Nair, S. C., Rimerman, R. A., Toran, E. J., Chen,
S. Y., Prapapanich, V., Butts, R. N. & Smith, D. F.
(1997). Mol. Cell. Biol. 17, 594±603.
P¯ugl, G., Kallen, J., Jansonius, J. M. &
Walkinshaw, M. D. (1994). J. Mol. Biol. 244,
385±409.
P¯ugl, G., Kallen, J., Schirmer, T., Jansonius, J. N.,
Zurini, M. G. M. & Walkinshaw, M. D. (1993).
Nature (London), 361, 91±94.
Pratt, W. B. & Toft, D. O. (1997). Endocrine Rev.
18, 306±360.
Radanyi, C., Chambraud, B. & Baulieu, E. E.
(1994). Proc. Natl Acad. Sci. USA, 91, 11197±
11201.
Ratajczak, T. & Carrello, A. (1996). J. Biol. Chem.
271, 2961±2965.
Ratajczak, T., Carrello, A., Mark, P. J., Warner,
B. J., Simpson, R. J., Moritz, R. L. & House,
A. K. (1993). J. Biol. Chem. 268, 13187±13192.
Rost, B., Sander, C. & Schneider, R. (1994).
Comput. Appl. Biosci. 10, 53±60.
Taylor, P., Page, A. P., Kondopidis, G., Husi, H. &
Walkinshaw, M. D. (1998). FEBS Lett. 425, 261±
366.
Weisman, R., Creanor, J. & Fantes, P. (1996).
EMBO J. 15, 447±456.
Yokoyama, N., Hayashi, N., Seki, T., Pante, N.,
Ohba, T., Nishii, K., Kuma, K., Hayashida, T.,
Miyata, Y., Aebi, U., Fukui, M. & Nishimoto, T.
(1995). Nature (London), 376, 184±188.
Young, J. C., Obermann, W. M. J. & Hartl, F. U.
(1998). J. Biol. Chem. 273, 18007±18010.
